Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Metrics to compare | IMU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMUPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.6x | −4.3x | −0.7x | |
PEG Ratio | −0.03 | −0.09 | 0.00 | |
Price/Book | 2.4x | 3.9x | 2.6x | |
Price / LTM Sales | 24.9x | 10.1x | 3.4x | |
Upside (Analyst Target) | - | 180.0% | 39.1% | |
Fair Value Upside | Unlock | 4.6% | 5.4% | Unlock |